Tool
Research Browser
Every benefit claim in our database is tagged with an evidence grade and a citation. Filter by category, grade, or substance and jump to PubMed when needed.
219 of 219 citations
| Substance | Benefit / endpoint | Evidence | Source | PubMed |
|---|---|---|---|---|
| 5-HTPamino-acid | Mood / depression support | EVIDENCEB | Older RCTs. | 460 |
| 5-HTPamino-acid | Sleep onset | EVIDENCEB | Small RCTs. | 460 |
| Acetyl-L-Carnitine (ALCAR)cholinergic | Cognitive function in mild cognitive impairment | EVIDENCEB | Multiple RCTs, meta-analysis. | 600 |
| Acetyl-L-Carnitine (ALCAR)cholinergic | Reduced mental fatigue | EVIDENCEB | Malaguarnera et al. 2008. | 600 |
| Adrafinilstimulant | Sustained wakefulness | EVIDENCEB | Via modafinil metabolite. | 60 |
| Agmatine Sulfateamino-acid | Neuropathic pain modulation | EVIDENCEB | Small RCTs. | 600 |
| Agmatine Sulfateamino-acid | Anxiolytic + antidepressant (animal models) | EVIDENCEC | Mechanistic. | 600 |
| Alpha Brainblend | Verbal memory and processing | EVIDENCEC | Solomon 2014 (Onnit-funded). | — |
| Alpha-GPCcholinergic | Memory and learning via increased ACh | EVIDENCEA | Multiple human RCTs. | 320 |
| Alpha-GPCcholinergic | Cognitive function in Alzheimer's | EVIDENCEA | De Jesus Moreno, 2003. | 320 |
| Alpha-GPCcholinergic | Growth hormone secretion | EVIDENCEB | Kawamura et al. 2012. | 320 |
| Alpha-GPCcholinergic | Power output in athletes | EVIDENCEB | Ziegenfuss et al. 2008. | 320 |
| Alpha-Lipoic Acidneuroprotective | Diabetic neuropathy | EVIDENCEA | ALADIN trials. | 1900 |
| Alpha-Lipoic Acidneuroprotective | Insulin sensitivity | EVIDENCEB | Multiple RCTs. | 1900 |
| Amphetamine (Adderall)stimulant | ADHD symptoms | EVIDENCEA | Hundreds of RCTs. | 24000 |
| Aniracetamracetam | Reduced anxiety without sedation | EVIDENCEB | Nakamura & Tanaka, 2001. | 280 |
| Aniracetamracetam | Creativity and holistic thinking | EVIDENCEC | Anecdotal + animal models. | 280 |
| Apigeninneuroprotective | Sleep quality / anxiety | EVIDENCEB | Small RCTs in chamomile extract. | 400 |
| Apigeninneuroprotective | CD38 inhibition / NAD+ preservation | EVIDENCEC | Mechanism + animal. | 400 |
| Armodafinilstimulant | Smoother wakefulness vs modafinil | EVIDENCEA | Direct head-to-head comparisons. | 380 |
| Ashwagandhaadaptogen | Cortisol reduction (~28%) | EVIDENCEA | Multiple RCTs, KSM-66 studied most. | 650 |
| Ashwagandhaadaptogen | Anxiety reduction | EVIDENCEA | Pratte et al. 2014 meta-analysis. | 650 |
| Ashwagandhaadaptogen | Sleep quality | EVIDENCEB | Salve et al. 2019. | 650 |
| Ashwagandhaadaptogen | Testosterone in men | EVIDENCEB | Lopresti et al. 2019. | 650 |
| B-Complexvitamin | Methylation / homocysteine | EVIDENCEA | Universally accepted. | 8000 |
| B-Complexvitamin | Mood support (when deficient) | EVIDENCEB | Multiple RCTs in deficient populations. | 8000 |
| BPC-157peptide | Tendon/ligament healing (animal models) | EVIDENCEC | Sikiric review. | 110 |
| BPC-157peptide | GI healing (animal models) | EVIDENCEC | Sikiric review. | 110 |
| Bacopa Monnieriadaptogen | Memory acquisition and retention | EVIDENCEA | Stough 2001; Roodenrys 2002. | 540 |
| Bacopa Monnieriadaptogen | Attention and processing speed | EVIDENCEA | Calabrese 2008 meta-analysis. | 540 |
| Bacopa Monnieriadaptogen | Anxiolytic / adaptogenic | EVIDENCEB | Multiple RCTs. | 540 |
| Beta-Alanineamino-acid | Anaerobic capacity | EVIDENCEA | Trexler 2015 meta-analysis. | 800 |
| CDP-Cholinecholinergic | Memory and attention | EVIDENCEA | Alvarez et al. 1997. | 420 |
| CDP-Cholinecholinergic | Stroke recovery | EVIDENCEA | ICTUS trial, Davalos 2002. | 420 |
| Caffeinestimulant | Alertness and reduced fatigue | EVIDENCEA | Universally supported. | 25000 |
| Caffeinestimulant | Reaction time and vigilance | EVIDENCEA | Lieberman et al. 2002. | 25000 |
| Caffeinestimulant | Synergy with L-theanine | EVIDENCEA | Multiple RCTs. | 25000 |
| Centrophenoxinecholinergic | Cognitive function in elderly | EVIDENCEB | European clinical trials. | 80 |
| Centrophenoxinecholinergic | Lipofuscin reduction | EVIDENCEC | Animal models. | 80 |
| Cerebrolysinpeptide | Stroke recovery | EVIDENCEB | Multiple European RCTs. | 380 |
| Cerebrolysinpeptide | Mild-to-moderate Alzheimer's | EVIDENCEC | Cochrane reviews mixed. | 380 |
| Chagaadaptogen | Antioxidant capacity | EVIDENCEB | Multiple in vitro and animal studies. | 280 |
| Chagaadaptogen | Immune support | EVIDENCEC | Animal models. | 280 |
| CoQ10neuroprotective | Statin-induced myalgia | EVIDENCEB | Banach 2015 meta-analysis. | 1700 |
| CoQ10neuroprotective | Cardiovascular outcomes in HF | EVIDENCEA | Q-SYMBIO trial. | 1700 |
| Coluracetamracetam | Vision / color perception | EVIDENCEC | Anecdotal + early human trials. | 15 |
| Coluracetamracetam | Anxiolytic / antidepressant | EVIDENCEC | Animal models for depression with anxiety. | 15 |
| Cordycepsadaptogen | Exercise performance | EVIDENCEB | Chen et al. 2010 RCT. | 240 |
| Cordycepsadaptogen | Anti-fatigue / energy | EVIDENCEC | Animal + small human trials. | 240 |
| Creatineamino-acid | Working memory under mental fatigue | EVIDENCEA | Rae 2003. | 1800 |
| Creatineamino-acid | Cognitive function during sleep deprivation | EVIDENCEA | McMorris 2006. | 1800 |
| Creatineamino-acid | Antidepressant effects | EVIDENCEB | Kious 2019. | 1800 |
| Curcumin (Turmeric)neuroprotective | Memory and attention | EVIDENCEB | Small 2018 RCT. | 14000 |
| Curcumin (Turmeric)neuroprotective | Depression | EVIDENCEB | Ng 2017 meta-analysis. | 14000 |
| Curcumin (Turmeric)neuroprotective | Joint inflammation | EVIDENCEA | Multiple RCTs. | 14000 |
| DMAEcholinergic | Mild focus enhancement | EVIDENCEC | Older European clinical use. | 110 |
| DMAEcholinergic | ADHD symptoms (historical) | EVIDENCEC | Studied as Deanol decades ago. | 110 |
| Dihexapeptide | Synaptogenesis (animal models) | EVIDENCEC | Wright lab studies. | 25 |
| Dihydromyricetin (DHM)amino-acid | Reduces alcohol intoxication symptoms | EVIDENCEB | Animal models; small human studies. | 380 |
| Dynamine (Methylliberine)stimulant | Acute energy and mood | EVIDENCEC | Limited human data. | 10 |
| EGCG (Green Tea)neuroprotective | Cardiovascular health | EVIDENCEA | Multiple meta-analyses. | 4800 |
| EGCG (Green Tea)neuroprotective | Metabolic rate / fat oxidation | EVIDENCEB | Multiple RCTs. | 4800 |
| Eleutheroadaptogen | Physical performance under stress | EVIDENCEB | Soviet sports medicine literature. | 240 |
| Eleutheroadaptogen | Cognitive endurance | EVIDENCEC | Limited human trials. | 240 |
| Fasoracetamracetam | ADHD symptoms in mGluR-mutation phenotype | EVIDENCEC | Pediatric trials by Aevi. | 20 |
| Fasoracetamracetam | Anxiolytic via GABA-B | EVIDENCEC | Animal models. | 20 |
| Fisetinneuroprotective | Senolytic activity in vivo | EVIDENCEB | Yousefzadeh 2018 EBioMedicine. | 1700 |
| Fisetinneuroprotective | Cognitive aging (animal models) | EVIDENCEC | Currais 2018. | 1700 |
| Folate (Methylfolate)vitamin | Depression (especially treatment-resistant) | EVIDENCEB | Papakostas 2014. | 9800 |
| Folate (Methylfolate)vitamin | Cognitive function in elderly | EVIDENCEB | Multiple RCTs. | 9800 |
| GABAamino-acid | Subjective relaxation / stress reduction | EVIDENCEC | Abdou 2006. | 320 |
| Galantaminecholinergic | Mild-to-moderate Alzheimer's | EVIDENCEA | Multiple RCTs. | 3800 |
| Galantaminecholinergic | Lucid dreaming (anecdotal) | EVIDENCEC | Popular for REM-stage dream induction. | 3800 |
| Ginkgo Bilobaherb | Memory in age-related decline | EVIDENCEB | Multiple meta-analyses. | 4200 |
| Ginkgo Bilobaherb | Tinnitus | EVIDENCEB | Hilton et al. 2013 Cochrane. | 4200 |
| Ginkgo Bilobaherb | Peripheral circulation | EVIDENCEA | Multiple RCTs. | 4200 |
| Glycineamino-acid | Sleep quality at bedtime | EVIDENCEB | Yamadera 2007. | 980 |
| Glycineamino-acid | Reduced subjective fatigue | EVIDENCEB | Bannai 2012. | 980 |
| Gotu Kolaadaptogen | Anxiety reduction | EVIDENCEB | Bradwejn et al. 2000. | 350 |
| Gotu Kolaadaptogen | Cognitive function | EVIDENCEB | Wattanathorn 2008. | 350 |
| Huperzine Acholinergic | Memory in Alzheimer's | EVIDENCEA | Wang et al. 2009 Cochrane review of 6 RCTs. | 380 |
| Huperzine Acholinergic | Learning in healthy individuals | EVIDENCEB | Several small RCTs. | 380 |
| Kannaadaptogen | Anxiety and mood | EVIDENCEB | Chiu 2014. | 50 |
| Kannaadaptogen | Cognitive flexibility | EVIDENCEB | Dimpfel 2018. | 50 |
| Kavaadaptogen | Anxiety | EVIDENCEA | Cochrane 2003 meta-analysis. | 600 |
| L-Carnitineamino-acid | Exercise recovery | EVIDENCEB | Multiple RCTs. | 3400 |
| L-Carnitineamino-acid | Cardiovascular health | EVIDENCEA | DiNicolantonio 2013 meta-analysis. | 3400 |
| L-Citrullineamino-acid | Exercise performance / endurance | EVIDENCEA | Multiple RCTs. | 1100 |
| L-Citrullineamino-acid | Erectile dysfunction (mild) | EVIDENCEB | Cormio 2011. | 1100 |
| L-Theanineamino-acid | Alpha brain wave activity / relaxed focus | EVIDENCEA | Nobre 2008. | 720 |
| L-Theanineamino-acid | Anxiety reduction without sedation | EVIDENCEA | Kimura 2007. | 720 |
| L-Theanineamino-acid | Synergy with caffeine | EVIDENCEA | Owen 2008. | 720 |
| L-Tryptophanamino-acid | Sleep onset and quality | EVIDENCEB | Multiple RCTs. | 1700 |
| L-Tryptophanamino-acid | Mood support | EVIDENCEB | Small RCTs. | 1700 |
| L-Tyrosineamino-acid | Cognitive performance under acute stress | EVIDENCEA | Deijen & Orlebeke 1994. | 480 |
| L-Tyrosineamino-acid | Working memory during multitasking | EVIDENCEB | Thomas 1999 military study. | 480 |
| L-Tyrosineamino-acid | Focus during sleep deprivation | EVIDENCEB | Neri 1995. | 480 |
| Lemon Balmadaptogen | Anxiety | EVIDENCEB | Multiple small RCTs. | 380 |
| Lemon Balmadaptogen | Cognitive function | EVIDENCEB | Kennedy 2003. | 380 |
| Lion's Maneadaptogen | NGF upregulation | EVIDENCEB | Mori et al. 2008. | 280 |
| Lion's Maneadaptogen | Mild cognitive impairment | EVIDENCEB | Mori et al. 2009 RCT. | 280 |
| Lion's Maneadaptogen | Anxiety and depression | EVIDENCEB | Nagano et al. 2010. | 280 |
| Lithium Orotatevitamin | Mood support (anecdotal + low-dose studies) | EVIDENCEC | Sartori 1986. | 30 |
| Lithium Orotatevitamin | Neuroprotection via BDNF | EVIDENCEC | Mechanism + animal models. | 30 |
| Macaadaptogen | Libido (both sexes) | EVIDENCEB | Multiple small RCTs. | 260 |
| Macaadaptogen | Mood / energy | EVIDENCEB | Brooks 2008. | 260 |
| Magic Mindblend | Convenient AM nootropic combo | EVIDENCEC | Ingredient evidence base. | — |
| Magnesium Glycinateneuroprotective | Sleep quality | EVIDENCEB | Multiple small RCTs. | 1200 |
| Magnesium Glycinateneuroprotective | Anxiety in deficient subjects | EVIDENCEB | Boyle 2017 review. | 1200 |
| Magnesium L-Threonateneuroprotective | Increased brain magnesium levels | EVIDENCEA | Slutsky 2010 Neuron. | 90 |
| Magnesium L-Threonateneuroprotective | Reduced 'brain age' by 9 years (human trial) | EVIDENCEB | Liu 2016. | 90 |
| Melatoninneuroprotective | Sleep onset | EVIDENCEA | Multiple meta-analyses. | 28000 |
| Melatoninneuroprotective | Jet lag | EVIDENCEA | Herxheimer 2009 Cochrane. | 28000 |
| Melatoninneuroprotective | Antioxidant | EVIDENCEB | Mechanism + animal. | 28000 |
| Metforminneuroprotective | Type 2 diabetes prevention/management | EVIDENCEA | Universally accepted. | 23000 |
| Metforminneuroprotective | Possible all-cause mortality reduction | EVIDENCEC | Bannister 2014. | 23000 |
| Methylphenidatestimulant | ADHD symptoms | EVIDENCEA | Hundreds of RCTs. | 7800 |
| Methylphenidatestimulant | Acute focus in non-ADHD | EVIDENCEA | Battleday 2015. | 7800 |
| Mind Lab Problend | All-day cognitive support | EVIDENCEB | Manufacturer studies + ingredient evidence. | — |
| Modafinilstimulant | Sustained wakefulness 12-15h | EVIDENCEA | Multiple RCTs. | 3200 |
| Modafinilstimulant | Working memory and executive function | EVIDENCEA | Battleday & Brem 2015 (24 studies). | 3200 |
| Mucuna Pruriensherb | Parkinson's disease (alternative L-DOPA source) | EVIDENCEB | Multiple small RCTs. | 320 |
| Mucuna Pruriensherb | Mood / motivation | EVIDENCEC | Anecdotal + small studies. | 320 |
| N-Acetyl Cysteine (NAC)amino-acid | OCD symptoms | EVIDENCEB | Several RCTs. | 5000 |
| N-Acetyl Cysteine (NAC)amino-acid | Addiction (craving reduction) | EVIDENCEB | Multiple RCTs. | 5000 |
| N-Acetyl Cysteine (NAC)amino-acid | Neuroprotection / antioxidant | EVIDENCEB | Mechanism + animal models. | 5000 |
| NMNneuroprotective | Increased NAD+ levels | EVIDENCEA | Multiple human RCTs. | 600 |
| NMNneuroprotective | Aerobic capacity / muscle function | EVIDENCEB | Yoshino 2021 Science. | 600 |
| Nefiracetamracetam | Memory and learning | EVIDENCEB | Animal models; Japanese clinical trials. | 30 |
| Nefiracetamracetam | Apathy in post-stroke patients | EVIDENCEB | Robinson 2009. | 30 |
| Neurohacker Eternusblend | Multi-pathway cellular aging support | EVIDENCEC | Manufacturer-funded studies. | — |
| Nicotinamide Riboside (NR)neuroprotective | NAD+ elevation | EVIDENCEA | Trammell 2016, Dollerup 2018. | 250 |
| Nicotinamide Riboside (NR)neuroprotective | Cardiovascular markers | EVIDENCEB | Martens 2018. | 250 |
| Nicotinestimulant | Attention and processing speed | EVIDENCEA | Heishman 2010 meta-analysis. | 13000 |
| Nicotinestimulant | Fine motor control | EVIDENCEA | Multiple lab studies. | 13000 |
| Noopeptpeptide | BDNF / NGF upregulation | EVIDENCEB | Rat studies, possibly extrapolable. | 90 |
| Noopeptpeptide | Anxiolytic + memory | EVIDENCEB | Russian clinical literature. | 90 |
| Omega-3 (DHA/EPA)neuroprotective | Structural component of brain membranes | EVIDENCEA | Universally accepted. | 5200 |
| Omega-3 (DHA/EPA)neuroprotective | Reduced age-related cognitive decline | EVIDENCEB | Morris 2003. | 5200 |
| Omega-3 (DHA/EPA)neuroprotective | Improved mood / reduced depression | EVIDENCEB | Sublette 2011 meta-analysis. | 5200 |
| Oxiracetamracetam | Logical thinking and analytical performance | EVIDENCEB | Multiple small RCTs. | 150 |
| Oxiracetamracetam | Memory formation | EVIDENCEB | Bottini et al., 1992. | 150 |
| PEA (Phenylethylamine)amino-acid | Acute mood / focus elevation | EVIDENCEC | Anecdotal + animal studies. | 1100 |
| PQQneuroprotective | Cognitive function | EVIDENCEC | Itoh 2016 small RCT. | 320 |
| PQQneuroprotective | Mitochondrial biogenesis | EVIDENCEB | Animal + mechanism. | 320 |
| Panax Ginseng (Korean)adaptogen | Cognitive function | EVIDENCEB | Reay et al. 2005. | 1100 |
| Panax Ginseng (Korean)adaptogen | Reduced fatigue | EVIDENCEB | Multiple RCTs. | 1100 |
| Performance Lab Mindblend | Cognitive support | EVIDENCEB | Ingredient evidence base. | — |
| Phenibutresearch_chemical | Acute anxiolytic / social anxiety | EVIDENCEC | Russian clinical use. | 110 |
| Phenylpiracetamracetam | Psychostimulant + anti-fatigue effects | EVIDENCEB | Russian military and athletic use. | 80 |
| Phenylpiracetamracetam | Cold tolerance and physical stamina | EVIDENCEC | Anecdotal + small studies. | 80 |
| Phosphatidylserine (PS)cholinergic | Memory in age-related cognitive decline | EVIDENCEB | Multiple RCTs. | 280 |
| Phosphatidylserine (PS)cholinergic | Reduced cortisol from exercise stress | EVIDENCEB | Starks et al. 2008. | 280 |
| Piracetamracetam | Verbal learning and memory | EVIDENCEA | Meta-analysis of 19 double-blind trials. | 1200 |
| Piracetamracetam | Cognitive function in elderly | EVIDENCEB | Improvement in patients with cognitive decline. | 1200 |
| Piracetamracetam | Neuroprotection | EVIDENCEB | Effects during oxygen deprivation. | 1200 |
| Pramiracetamracetam | Long-term memory formation | EVIDENCEB | Studies in amnesic patients. | 60 |
| Pramiracetamracetam | Focus and analytical clarity | EVIDENCEC | Anecdotal + animal models. | 60 |
| Pterostilbeneneuroprotective | Cardiovascular markers | EVIDENCEB | Riche 2014. | 280 |
| Pterostilbeneneuroprotective | Neuroprotection / cognition | EVIDENCEC | Animal models. | 280 |
| Qualia Mindblend | Acute multi-pathway cognitive support | EVIDENCEC | Manufacturer-funded studies. | — |
| Qualia Nightblend | Sleep quality | EVIDENCEC | Manufacturer-funded studies. | — |
| Quercetinneuroprotective | Cardiovascular markers | EVIDENCEB | Multiple meta-analyses. | 4600 |
| Quercetinneuroprotective | Allergic rhinitis | EVIDENCEB | Small RCTs. | 4600 |
| Rapamycinneuroprotective | Lifespan extension in mice | EVIDENCEA | Multiple replicated studies. | 36000 |
| Rapamycinneuroprotective | Immune system rejuvenation | EVIDENCEB | Mannick 2014. | 36000 |
| Reishiadaptogen | Sleep quality | EVIDENCEB | Chu et al. 2007. | 460 |
| Reishiadaptogen | Anti-fatigue | EVIDENCEC | Tang et al. 2005. | 460 |
| Reishiadaptogen | Immune modulation | EVIDENCEB | Many RCTs in oncology adjunct. | 460 |
| Resveratrolneuroprotective | Endothelial function | EVIDENCEB | Multiple RCTs. | 16000 |
| Resveratrolneuroprotective | Insulin sensitivity | EVIDENCEC | Mixed evidence. | 16000 |
| Rhodiola Roseaadaptogen | Mental fatigue under stress | EVIDENCEA | Darbinyan et al. 2000. | 460 |
| Rhodiola Roseaadaptogen | Burnout symptoms | EVIDENCEB | Edwards et al. 2012. | 460 |
| Rhodiola Roseaadaptogen | Mild depression | EVIDENCEB | Mao et al. 2015. | 460 |
| SAMevitamin | Major depressive disorder | EVIDENCEA | Williams 2010 meta-analysis. | 2100 |
| SAMevitamin | Osteoarthritis | EVIDENCEA | Soeken 2002. | 2100 |
| Saffronadaptogen | Mild-to-moderate depression | EVIDENCEA | Multiple meta-analyses non-inferior to fluoxetine. | 1700 |
| Saffronadaptogen | ADHD symptoms | EVIDENCEB | Baziar 2019; Khaksarian 2021. | 1700 |
| Saffronadaptogen | Premenstrual syndrome | EVIDENCEB | Multiple RCTs. | 1700 |
| Schisandraadaptogen | Mental performance under stress | EVIDENCEB | Panossian 2008 review. | 380 |
| Schisandraadaptogen | Liver protection | EVIDENCEA | Multiple RCTs. | 380 |
| Selankpeptide | Anxiolytic | EVIDENCEC | Russian RCTs. | 50 |
| Seleniumvitamin | Thyroid function (autoimmune thyroiditis) | EVIDENCEB | Toulis 2010. | 4400 |
| Seleniumvitamin | Antioxidant support | EVIDENCEA | Mechanism + epidemiology. | 4400 |
| Semaxpeptide | Cognition / focus | EVIDENCEC | Russian clinical trials. | 80 |
| Semaxpeptide | Stroke recovery | EVIDENCEB | Russian RCTs. | 80 |
| Spanish Sageherb | Memory and mood | EVIDENCEB | Tildesley 2003. | 50 |
| Spermidineneuroprotective | All-cause mortality reduction | EVIDENCEB | Kiechl 2018 prospective. | 6800 |
| Spermidineneuroprotective | Cognitive aging | EVIDENCEB | Wirth 2018. | 6800 |
| Sulbutiaminestimulant | Asthenia / chronic fatigue | EVIDENCEB | Tiev et al. 1999. | 50 |
| Sulbutiaminestimulant | Mood and motivation | EVIDENCEC | Anecdotal + small studies. | 50 |
| Taurineamino-acid | Neuroprotection against excitotoxicity | EVIDENCEB | Animal studies. | 950 |
| Taurineamino-acid | Anxiolytic / calming via GABA-A | EVIDENCEB | Multiple studies. | 950 |
| Taurineamino-acid | Lifespan extension in mice (~10-12%) | EVIDENCEC | Singh 2023 Science. | 950 |
| Theacrinestimulant | Sustained energy without tolerance | EVIDENCEB | Taylor 2016. | 50 |
| Theacrinestimulant | Mental clarity | EVIDENCEB | Multiple sponsor-funded RCTs. | 50 |
| Thesis (Personalized Blends)blend | Marketing-driven personalization model | EVIDENCEC | Manufacturer claims; no published RCTs. | — |
| Tongkat Aliadaptogen | Testosterone support in stress | EVIDENCEB | Talbott et al. 2013. | 180 |
| Tongkat Aliadaptogen | Stress and mood | EVIDENCEB | Smaller RCTs. | 180 |
| Tulsi (Holy Basil)adaptogen | Stress and anxiety | EVIDENCEB | Cohen 2014 review. | 380 |
| Tulsi (Holy Basil)adaptogen | Blood glucose support | EVIDENCEB | Multiple RCTs. | 380 |
| Turkey Tailadaptogen | Immune support during chemotherapy | EVIDENCEA | Multiple Japanese RCTs. | 400 |
| Valerian Rootadaptogen | Sleep latency | EVIDENCEB | Bent 2006 meta-analysis. | 460 |
| Valerian Rootadaptogen | Mild anxiety | EVIDENCEB | Multiple RCTs. | 460 |
| Vinpocetineneuroprotective | Cerebrovascular insufficiency | EVIDENCEB | European prescription use. | 600 |
| Vinpocetineneuroprotective | Cognitive function in vascular dementia | EVIDENCEB | Multiple RCTs. | 600 |
| Vitamin B12vitamin | Cognitive function (when deficient) | EVIDENCEA | Multiple RCTs in deficient subjects. | 18000 |
| Vitamin B12vitamin | Energy / fatigue (when deficient) | EVIDENCEA | Universally accepted. | 18000 |
| Vitamin B6 (P5P)vitamin | PMS symptoms | EVIDENCEB | Wyatt 1999 meta-analysis. | 7800 |
| Vitamin B6 (P5P)vitamin | Cognitive function in deficient elderly | EVIDENCEB | Multiple RCTs. | 7800 |
| Vitamin D3vitamin | Mood / mild depression | EVIDENCEB | Spedding 2014 meta-analysis (high-quality subset). | 9200 |
| Vitamin D3vitamin | Cognitive function in deficient elderly | EVIDENCEB | Multiple RCTs. | 9200 |
| Vitamin D3vitamin | Immune function | EVIDENCEA | Universally accepted. | 9200 |
| Vitamin K2 (MK-7)vitamin | Cardiovascular health (arterial calcification) | EVIDENCEB | Knapen 2015. | 1200 |
| Vitamin K2 (MK-7)vitamin | Bone density (postmenopausal) | EVIDENCEB | Multiple RCTs. | 1200 |
| Yohimbinestimulant | Increased lipolysis (fasted) | EVIDENCEB | Multiple RCTs. | 720 |
| Yohimbinestimulant | Erectile dysfunction | EVIDENCEB | Older RCTs. | 720 |
| Zincvitamin | Cold duration | EVIDENCEA | Cochrane 2013. | 5400 |
| Zincvitamin | Mild depression (deficient) | EVIDENCEB | Lai 2012 meta-analysis. | 5400 |